

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Ascletis Pharma Inc.

歌禮製藥有限公司

(incorporated in the Cayman Islands with limited liability)

(Stock Code: 1672)

VOLUNTARY ANNOUNCEMENT VIRAL DISEASE BUSINESS UPDATE

This announcement is made by Ascletis Pharma Inc. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis for the purpose of keeping the shareholders of the Company and potential investors abreast of the latest business development of the Group.

The board of directors (the “**Board**”) of the Company announces an update in connection with the Group’s business of ritonavir tablets and ASC22.

Ritonavir Tablets

As of the date of this announcement, the receipt in advance for ritonavir tablets for the year of 2023 has reached approximately RMB55 million (tax inclusive, unaudited) based on irrevocable orders.

Given the continuous uncertainty of COVID-19 pandemic in 2023, the Company remains cautious on revenue generated from sale of ritonavir tablets for the full year of 2023.

ASC22

As of the date of this announcement, out of a total of 50 planned patients, 29 chronic hepatitis B patients with the baseline HBsAg $\leq$ 100 IU/mL have been enrolled in Phase IIb expansion cohort of subcutaneously administered PD-L1 antibody ASC22 (Envafolimab) for functional cure. Interim results from this Phase IIb expansion cohort are expected to be published in the third quarter of 2023.

Cautionary Statement required by Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: We cannot guarantee that we will be able to ultimately commercialize ASC22 successfully.

By order of the Board
Asclepis Pharma Inc.
歌禮製藥有限公司
Jinzi Jason WU
Chairman

Hangzhou, the People's Republic of China
March 20, 2023

As at the date of this announcement, the Board comprises Dr. Jinzi Jason WU and Mrs. Judy Hejingdao WU, as executive Directors; and Dr. Yizhen WEI, Mr. Jiong GU and Ms. Lin HUA, as independent non-executive Directors.